• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心境障碍的患病率和发病率研究:文献系统综述

Prevalence and incidence studies of mood disorders: a systematic review of the literature.

作者信息

Waraich Paul, Goldner Elliot M, Somers Julian M, Hsu Lorena

机构信息

Mental Health Evaluation and Community Consultation Unit, University of British Columbia, Vancouver.

出版信息

Can J Psychiatry. 2004 Feb;49(2):124-38. doi: 10.1177/070674370404900208.

DOI:10.1177/070674370404900208
PMID:15065747
Abstract

OBJECTIVE

To present the results of a systematic review of literature published between January 1, 1980, and December 31, 2000, that reports findings on the prevalence and incidence of mood disorders in both general population and primary care settings.

METHOD

We conducted a literature search of epidemiologic studies of mood disorders, using Medline and HealthSTAR databases and canvassing English-language publications. Eligible publications were restricted to studies that examined subjects aged at least 15 years and over. We used a set of predetermined inclusion and exclusion criteria to identify relevant studies. We extracted and analyzed prevalence and incidence data for heterogeneity.

RESULTS

Of general population studies, a total of 18 prevalence and 5 incidence studies met eligibility criteria. We found heterogeneity across 1-year and lifetime prevalence of major depressive disorder (MDD), dysthymic disorder and bipolar I disorder. The corresponding pooled rates for 1-year prevalence were 4.1 per 100, 2.0 per 100, and 0.72 per 100, respectively. For lifetime prevalence, the corresponding pooled rates were 6.7 per 100, 3.6 per 100, and 0. per 100, respectively. Significant variation was observed among 1-year incidence rates of MDD, with a correspond ing pooled rate of 2.9 per 100.

CONCLUSIONS

The prevalence of mood disorders reported in high-quality studies is generally lower than rates commonly reported in the general psychiatric literature. When controlled for common methodological confounds, variation in prevalence rates persists across studies and deserves continued study. Methodological variation among studies that have examined the prevalence of depression in primary health care services is so large that comparative analyses cannot be achieved.

摘要

目的

呈现对1980年1月1日至2000年12月31日期间发表的文献进行系统综述的结果,这些文献报告了普通人群和初级保健机构中情绪障碍的患病率和发病率。

方法

我们使用Medline和HealthSTAR数据库对情绪障碍的流行病学研究进行文献检索,并查阅英文出版物。符合条件的出版物仅限于研究年龄至少为15岁及以上受试者的研究。我们使用一组预先确定的纳入和排除标准来识别相关研究。我们提取并分析患病率和发病率数据以评估异质性。

结果

在普通人群研究中,共有18项患病率研究和5项发病率研究符合资格标准。我们发现重度抑郁症(MDD)、心境恶劣障碍和双相I型障碍的1年患病率和终生患病率存在异质性。1年患病率的相应合并率分别为每100人中有4.1例、2.0例和0.72例。对于终生患病率,相应的合并率分别为每100人中有6.7例、3.6例和0例。观察到MDD的1年发病率存在显著差异,相应的合并率为每100人中有2.9例。

结论

高质量研究报告的情绪障碍患病率通常低于普通精神病学文献中通常报告的患病率。在控制常见的方法学混杂因素后,研究之间患病率的差异仍然存在,值得继续研究。在初级卫生保健服务中检查抑郁症患病率的研究之间的方法学差异如此之大,以至于无法进行比较分析。

相似文献

1
Prevalence and incidence studies of mood disorders: a systematic review of the literature.心境障碍的患病率和发病率研究:文献系统综述
Can J Psychiatry. 2004 Feb;49(2):124-38. doi: 10.1177/070674370404900208.
2
Lithium for maintenance treatment of mood disorders.锂盐用于心境障碍的维持治疗。
Cochrane Database Syst Rev. 2001(3):CD003013. doi: 10.1002/14651858.CD003013.
3
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
4
Lithium for maintenance treatment of mood disorders.锂盐用于心境障碍的维持治疗。
Cochrane Database Syst Rev. 2001;2001(2):CD003013. doi: 10.1002/14651858.CD003013.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.纤维素、改性纤维素和合成膜在终末期肾病患者血液透析中的比较。
Cochrane Database Syst Rev. 2001(3):CD003234. doi: 10.1002/14651858.CD003234.
7
Antidepressants for the treatment of depression in people with cancer.用于治疗癌症患者抑郁症的抗抑郁药。
Cochrane Database Syst Rev. 2018 Apr 23;4(4):CD011006. doi: 10.1002/14651858.CD011006.pub3.
8
Prevalence and incidence studies of anxiety disorders: a systematic review of the literature.焦虑症的患病率和发病率研究:文献系统综述
Can J Psychiatry. 2006 Feb;51(2):100-13. doi: 10.1177/070674370605100206.
9
Pharmacological interventions for people with borderline personality disorder.药物干预治疗边缘型人格障碍患者。
Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD012956. doi: 10.1002/14651858.CD012956.pub2.
10
Omega-3 fatty acids for depression in adults.ω-3 脂肪酸治疗成人抑郁症。
Cochrane Database Syst Rev. 2021 Nov 24;11(11):CD004692. doi: 10.1002/14651858.CD004692.pub5.

引用本文的文献

1
Amygdala volume abnormalities and cognitive impairment in major depressive disorder and bipolar disorder II.重度抑郁症和双相情感障碍II型中的杏仁核体积异常与认知障碍
BMC Psychiatry. 2025 Aug 28;25(1):839. doi: 10.1186/s12888-025-07313-1.
2
Expanding our understanding of (mal)adapted stress physiology in psychiatric disorders: achieving single-cell characterisation of steroids and neuropeptides.拓展我们对精神疾病中(不)适应性应激生理学的理解:实现类固醇和神经肽的单细胞特征分析
Neurobiol Stress. 2025 Jun 6;37:100739. doi: 10.1016/j.ynstr.2025.100739. eCollection 2025 Jul.
3
Anxiety, depression, physical disease parameters and health-related quality of life in the BronchUK national bronchiectasis cohort.
英国支气管扩张症全国队列中的焦虑、抑郁、身体疾病参数及健康相关生活质量
ERJ Open Res. 2025 May 27;11(3). doi: 10.1183/23120541.00348-2024. eCollection 2025 May.
4
From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation.从应激到突触:神经元萎缩导致情绪失调的途径。
Int J Mol Sci. 2025 Mar 30;26(7):3219. doi: 10.3390/ijms26073219.
5
High Frequency of Depression in Advanced Cancer with Concomitant Comorbidities: A Registry Study.晚期癌症合并共病时抑郁症的高发生率:一项登记研究
Cancers (Basel). 2025 Apr 3;17(7):1214. doi: 10.3390/cancers17071214.
6
Functional vs Structural Cortical Deficit Pattern Biomarkers for Major Depressive Disorder.重度抑郁症的功能性与结构性皮质缺陷模式生物标志物
JAMA Psychiatry. 2025 Apr 2. doi: 10.1001/jamapsychiatry.2025.0192.
7
Neuropsychiatric complications in chronic kidney disease: Role of gender, clinical, and sociodemographic factors.慢性肾脏病中的神经精神并发症:性别、临床及社会人口学因素的作用
J Family Med Prim Care. 2024 Nov;13(11):5077-5082. doi: 10.4103/jfmpc.jfmpc_607_24. Epub 2024 Nov 18.
8
The prevalence of depression and anxiety in patients with metastatic disease to the spine.脊柱转移性疾病患者中抑郁和焦虑的患病率。
J Craniovertebr Junction Spine. 2024 Jul-Sep;15(3):308-314. doi: 10.4103/jcvjs.jcvjs_23_24. Epub 2024 Sep 12.
9
Trends in Anxiety and Depression Among Individuals With Rheumatoid Arthritis: A Population-Based Study.类风湿关节炎患者焦虑和抑郁的趋势:一项基于人群的研究。
J Rheumatol. 2025 Mar 1;52(3):210-218. doi: 10.3899/jrheum.2024-0165.
10
Tocilizumab Reduces Depression Risk in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.托珠单抗降低类风湿关节炎患者的抑郁风险:一项系统评价和荟萃分析。
Psychol Res Behav Manag. 2024 Oct 4;17:3419-3441. doi: 10.2147/PRBM.S482409. eCollection 2024.